Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAnthem Orencia (abatacept) Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0078

    Orencia (abatacept) — Clinical Medical Policy (coverage criteria)

    Customize your policy alerts

    Sign up for Anthem Policy CC-0078 alerts

    Get alerted when Policy CC-0078 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical medical policy governing prior authorization, step therapy, quantity limits, and coverage criteria for Orencia (abatacept) for Anthem members, including indications such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, GVHD prophylaxis, chronic GVHD, and immune checkpoint inhibitor–related toxicities.

    Policy Summary
    PayerAnthem
    PolicyOrencia (abatacept) — Clinical Medical Policy (coverage criteria)
    Policy CodePolicy CC-0078
    Change TypeMaterial revisions (coverage and documentation updates, added indications, coding updates)
    Effective DateMar 26, 2026
    Last ReviewFeb 20, 2026
    Next Review DateFeb 20, 2026
    Key ActionPrior authorization requires documentation that the member meets indication-specific clinical criteria or is maintained on Orencia; GVHD prophylaxis requires use with a calcineurin inhibitor and methotrexate.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Updated 'may not approve' section; removed infection and tuberculosis testing requirements.

    Added indication language for immune checkpoint inhibitor–related toxicities per NCCN.

    Added prophylaxis of acute graft-versus-host disease indication and corresponding quantity limit per label.

    Update may not approve section; remove infection and tuberculosis testing requirements.

    Coding Reviewed: Updated description for HCPCS J0129 and added multiple ICD-10-CM codes including D89.810 and T45.AX5A-T45.AX5S.

    Select Review: Update may not approve section; remove infection and tuberculosis testing requirements.

    6+covered indications
    4 vialsIV qty limit (28 days)
    4 syringesSC qty limit (28 days)
    Day -1,5,14,28GVHD IV dosing schedule
    J0129HCPCS
    ICD-10 additionsICD-10 additions

    Coverage Criteria for Orencia (abatacept)

    Initial Therapy

    Initial requests may be approved when ALL indication-specific requirements are met as outlined below.

    Rheumatoid arthritis (RA) initial: Individual is 18 years of age or older with moderate to severe RA AND (has had an inadequate response to methotrexate titrated to maximally tolerated dose OR if methotrexate not tolerated, has had an inadequate response to or is intolerant of other conventional therapy [sulfasalazine, leflunomide, or hydroxychloroquine] OR has a contraindication to methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine).
    Polyarticular juvenile idiopathic arthritis (PJIA) initial: Individual has moderate to severe PJIA AND is 6 years of age or older for IV infusion or 2 years of age or older for subcutaneous injection AND (has had an inadequate response to, or is intolerant of conventional therapy [nonbiologic DMARDs, such as methotrexate] OR has a contraindication to methotrexate).
    Psoriatic arthritis (PsA) initial: Individual is 2 years of age or older with moderate to severe PsA AND (has had an inadequate response to, or is intolerant of conventional therapy [nonbiologic DMARDs such as methotrexate, sulfasalazine, cyclosporine, or leflunomide] OR has a contraindication to methotrexate, sulfasalazine, cyclosporine, and leflunomide).
    Acute GVHD prophylaxis initial: Individual is 2 years of age or older using Orencia for prophylaxis of acute graft-versus-host disease AND will be undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele‑mismatched unrelated donor AND Orencia will be used in combination with a calcineurin inhibitor and methotrexate.
    Chronic GVHD (NCCN 2A) initial: Individual has a diagnosis of steroid‑refractory chronic GVHD AND is initiating abatacept in combination with systemic corticosteroids.
    Immune checkpoint inhibitor therapy‑related toxicities (NCCN 2A) initial: Individual is undergoing immune checkpoint inhibitor therapy for a cancer diagnosis AND is experiencing immunotherapy‑related myocarditis unresponsive to high‑dose systemic corticosteroids OR is experiencing concomitant immunotherapy‑related myositis and myocarditis.

    Continuation Therapy

    Continuation requests may be approved when ALL of the following are met:

    Continuation of therapy: Individual has been receiving and is maintained on a stable dose of Orencia AND there is confirmation of clinically significant improvement or stabilization in clinical signs and symptoms of the disease.

    May Not Approve

    Requests may not be approved when ANY of the following are present:

    Combination exclusions: Use in combination with topical or oral JAK inhibitors, ozanimod, etrasimod, apremilast, deucravacitinib, or any of the following biologic immunomodulators: TNF antagonists, IL‑23 inhibitors, IL‑17 inhibitors, vedolizumab, ustekinumab, IL‑1 inhibitors, IL‑6 inhibitors, rituximab, or natalizumab.
    Criteria not met or non‑listed indications: When the above indication‑specific criteria are not met and for all other indications not listed as approved.

    Benefit-specific coverage stance

    Coverage and step therapy stance by benefit

    Commercial Medical Benefit: Commercial benefit includes step therapy with Orencia listed as Non‑Preferred; preferred agents include a preferred infliximab product and Simponi Aria.

    See step therapy table and preferred agent listings for indication‑specific requirements.

    Medicaid Medical Benefit: Medicaid listings across multiple states designate Avsola as Preferred and Orencia as Non‑Preferred; effective dates vary by state.

    State‑specific effective dates are provided in the benefit table.

    Medicare Medical Benefit: Medicare: step therapy does not currently apply to this policy.

    Requests for Orencia (abatacept) in combination with certain agents are excluded from approval. Specifically, use in combination with topical or oral JAK inhibitors, ozanimod, etrasimod, apremilast, deucravacitinib, or any of the listed biologic immunomodulators (including TNF antagonists, IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, IL-1 inhibitors, IL-6 inhibitors, rituximab, or natalizumab) is not approvable.

    The policy’s combination-exclusion language has been updated historically. Recent document history notes an operational revision (02/20/2026) that modified the may not approve section; additional agents were considered in prior coding and step-therapy updates (see document history for dates and details).

    Use of Orencia (abatacept) for any indication not explicitly listed in the coverage criteria, or when the indication-specific criteria in this policy are not met, may not be approved.

    The policy’s may not approve/denial language was updated during a select review on 02/20/2026. That revision adjusted the non-approval section and removed prior infection and tuberculosis testing requirements; specific non-medically necessary conditions are described in the criteria but additional operational details were updated in the document history.

    Coding, Quantity Limits, and Formulary Status

    HCPCSHCPCS
    J0129Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) [Orencia]
    ICD-10 DiagnosisICD-10
    D89.810-D89.813Graft-versus-host disease
    I40.8-I40.9Acute myocarditis
    L40.50-L40.59Arthropathic psoriasis
    M05.00-M05.ARheumatoid arthritis with rheumatoid factor
    M06.00-M06.09Rheumatoid arthritis without rheumatoid factor
    M06.4Inflammatory polyarthropathy
    M06.80-M06.9Other specified and unspecified rheumatoid arthritis
    M08.00-M08.09Unspecified juvenile rheumatoid arthritis
    M08.20-M08.29Juvenile rheumatoid arthritis with systemic onset
    M08.3Juvenile rheumatoid polyarthritis (seronegative)
    1–10 of 14
    1/2
    Updated/Added Codesmixed
    J0129HCPCS J0129 (description updated)
    D89.810ICD-10-CM D89.810 (added)
    D89.811ICD-10-CM D89.811 (added)
    D89.812ICD-10-CM D89.812 (added)
    D89.813ICD-10-CM D89.813 (added)
    I40.8ICD-10-CM I40.8 (added)
    I40.9ICD-10-CM I40.9 (added)
    M60.80ICD-10-CM M60.80 (added)
    M60.9ICD-10-CM M60.9 (added)
    M05.AICD-10-CM M05.A (added effective 10/1/25)
    1–10 of 12
    1/2
    Formulary Statusmixed
    Preferred AgentsPreferred agents listings vary by benefit and state (e.g., Preferred infliximab product, Simponi Aria, Avsola).
    Non-Preferred AgentsOrencia listed as Non-Preferred in Commercial and Medicaid listings.
    Quantity limits (IV vial)
    Drug and presentationOrencia (abatacept) 250 mg per vial (intravenous)
    Quantity limitLimit = 4 vials per 28 days
    Override at initiationMay approve additional IV vials for initiation per protocol (see policy override criteria)
    Quantity limits (SC)
    Drug and presentationOrencia prefilled syringe/ClickJect autoinjector (50 mg, 87.5 mg, 125 mg) — subcutaneous
    Quantity limitLimit = 4 syringes/autoinjectors per 28 days

    Provider Actions, Prior Authorization and Step Therapy

    Prior Authorization

    Indication-specific prior authorization

    Prior authorization is required and is indication-specific. Requests must demonstrate the member meets the clinical criteria for the requested indication (age, diagnosis severity, indication-specific requirements, and prior trial history or contraindications to conventional therapy) as described in the Clinical Criteria. Benefits may also impose additional plan-level requirements (for example, use of preferred agents or step therapy) even when clinical criteria are met.

    • Applies to initial and continuation requests across indicated diagnoses.
    • Prior authorization decisions reference the Clinical Criteria section for indication-specific thresholds (age, prior DMARD trials, intolerance, contraindication).
    Denial Risk

    Combination and criteria failure

    Requests may be denied when Orencia is requested in combination with certain agents or when combination/continuation criteria are not met. Specifically, Orencia will not be approved in combination with oral or topical JAK inhibitors, ozanimod, etrasimod, apremilast, deucravacitinib, or listed biologic immunomodulators (including TNF antagonists, IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, IL-1 inhibitors, IL-6 inhibitors, rituximab, or natalizumab).

    Background on Abatacept and Indications

    Abatacept (Orencia) is a selective costimulation modulator that inhibits T‑lymphocyte activation. It is FDA‑approved for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis in IV and subcutaneous formulations. Additionally, abatacept is FDA‑approved for prophylaxis of acute graft‑versus‑host disease when given IV starting Day -1 with infusions on days 5, 14, and 28 in combination with a calcineurin inhibitor and methotrexate for hematopoietic stem cell transplant from matched or 1 allele‑mismatched unrelated donors. The agent is also used off‑label per NCCN guidance (2A) for certain steroid‑refractory chronic GVHD and for select immune checkpoint inhibitor–related toxicities such as myocarditis and concomitant myositis with myocarditis.

    Key Definitions and Specific Indication Notes

    Acute GVHD prophylaxis — IV dosing schedule
    IndicationAcute graft-versus-host disease (GVHD) prophylaxis in HSCT recipients from matched or 1 allele-mismatched unrelated donors
    Concomitant therapy requirementMust be used in combination with a calcineurin inhibitor and methotrexate
    Dosing schedule (IV)Administer IV starting Day -1 (the day before transplantation), then on Days 5, 14, and 28 after transplantation
    AgeAdults and pediatric patients 2 years of age and older
    Immunotherapy-related toxicities
    Guidance referencedNCCN Management of Immunotherapy-related Toxicities, V1.2025 (Management of Immunotherapy-related Toxicities. V1.2025; Revised December 20, 2024)

    Document Revision History

    2026-02-20Select Review (material)Latest

    Updated 'May Not Approve' section to remove infection and tuberculosis testing requirements; coding reviewed with no changes.

    2025-11-14Annual Review

    Step therapy updated; coding description for HCPCS J0129 updated and multiple ICD-10-CM codes (D89.810, T45.AX5A-T45.AX5S) added.

    2025-09-24Coding Update
    Policy Summary
    PayerAnthem
    PolicyOrencia (abatacept) — Clinical Medical Policy (coverage criteria)
    Policy CodePolicy CC-0078
    Change TypeMaterial revisions (coverage and documentation updates, added indications, coding updates)
    Effective DateMar 26, 2026
    Last ReviewFeb 20, 2026
    Next Review DateFeb 20, 2026
    Key ActionPrior authorization requires documentation that the member meets indication-specific clinical criteria or is maintained on Orencia; GVHD prophylaxis requires use with a calcineurin inhibitor and methotrexate.
    SourceLink
    On This Page
    Coverage Criteria for Orencia (abatacept)Coding, Quantity Limits, and Formulary StatusProvider Actions, Prior Authorization and Step TherapyBackground on Abatacept and IndicationsKey Definitions and Specific Indication NotesDocument Revision History
    Administration noteSC formulations are subject to the same 28-day quantity limit as IV; billing/use per product labeling
    • Combination exclusions apply regardless of indication unless otherwise specified.
    • Combination use with the listed agents is a basis for denial of the request.
    Denial Risk

    May Not Approve Risk

    May-not-approve (denial) decisions will be issued when the request does not meet the clinical criteria or when excluded combinations are present. Reviewers may also deny requests when required supporting information is not provided or when plan-level step therapy requirements are not satisfied.

    • Failure to meet indication-specific clinical criteria = denial.
    • Presence of excluded combinations (see Combination and criteria failure) = denial.
    • Noncompliance with step therapy or lack of documentation of preferred-agent trials may result in denial.
    Documentation Required

    Required clinical documentation

    Providers must submit documentation demonstrating the indication-specific criteria are met. Documentation should include: diagnosis and severity, patient age, prior treatment history including trials and outcomes (dose, duration, reason for discontinuation or intolerance), contraindications to conventional therapies, and for continuation requests, evidence of clinical benefit or stability on current therapy.

    • Document prior trials of methotrexate or other conventional DMARDs (or reason for intolerance/contraindication).
    • For step therapy, document trials of preferred agents (agent name, dose, duration, and reason for failure/intolerance).
    • For continuation, document stable dose and clinical improvement or stabilization.
    Documentation Required

    Documentation Updates

    Administrative documentation requirements have been updated periodically. Recent updates removed certain prior infection and tuberculosis testing requirements and clarified documentation expectations for rheumatoid arthritis and other indications. Providers should follow the latest documentation guidance and include historical trial and intolerance information.

    • 02/20/2026: Updated may-not-approve language; removed infection and TB testing requirements.
    • 07/01/2025 and 03/01/2024: Administrative updates to documentation requirements; see Document History for specifics.
    Step Therapy

    Step therapy requirements

    Step therapy requirements apply by benefit type and indication. Commercial and some Medicaid benefits require trials of preferred targeted immune modulators prior to approval of Orencia unless the member is already receiving Orencia, has had inadequate response or intolerance to the required number of preferred agents, or has contraindications to all preferred agents. Medicare currently does not apply step therapy.

    • Commercial RA and PsA: approval if currently on Orencia, OR trialed and failed TWO preferred agents, OR documented inability to use all preferred agents.
    • Commercial PJIA: approval if currently on Orencia, OR trialed and failed ONE preferred agent, OR documented inability to use all preferred agents (special-case for infliximab noted).
    • Medicaid (CA,NJ,OH and other states as listed): typically requires trial of ONE preferred agent prior to Orencia unless other criteria met.
    • Medicare Medical Benefit: step therapy does not currently apply.
    Applicable conditionsImmunotherapy-related myocarditis unresponsive to high‑dose systemic corticosteroids, or concomitant myositis and myocarditis
    Policy stanceUse and management of these toxicities are to follow the referenced NCCN guidance as cited in the policy

    Added ICD-10-CM M05.A effective 2025-10-01.

    2025-07-01Administrative Update

    Removed documentation requirement for Rheumatoid Arthritis.

    2025-05-01Step Therapy Update

    Updated step therapy tables.

    2025-04-01Step Therapy Update

    Updated step therapy tables.

    2025-02-03Step Therapy Update

    Step therapy and step therapy table updates implemented.

    2024-11-15Annual Review (material)

    Updated use in immunotherapy-related toxicities per NCCN and updated step therapy effective 2025-01-01; added ICD-10-CM codes D89.811-D89.813, I40.8-I40.9, M60.80-M60.9.

    2024-09-10Step Therapy Update

    Step therapy table updates.

    2024-03-01Administrative Update

    Added administrative documentation.

    2023-11-17Annual Review (material)

    Added immunotherapy-related toxicities and chronic GVHD per NCCN, added pediatric psoriatic arthritis indication, clarified contraindication language, clarified repeat TB testing requirements, included etrasimod in combination exclusion, and added continuation of use language.

    2023-11-18Annual Review

    Updated combination exclusion to include additional agents and specified biologic immunomodulators; added DMARD examples and formatting updates.

    2022-09-30Step Therapy Update

    Step therapy table updates.

    2022-02-25Select Review (material)

    Added new indication for prophylaxis of acute graft-versus-host disease to clinical criteria and added quantity limit per label.

    2021-11-19Annual Review

    Clarified tuberculosis testing requirements, aligned RA criteria with guidelines, removed option of prior TNF trial, updated references, and updated exclusion list for combination use.

    2021-10-25Step Therapy Update

    Updated step therapy table and made administrative step therapy updates.

    2020-11-20Annual Review

    Added continuation of use section and updated tuberculosis testing language.

    2020-10-29Administrative Update

    Added drug-specific quantity limits.